Lipid-based Therapeutics Addressing Cancer and Complex Diseases

Our unique lipid structures can navigate complex biological systems such as the tumor microenvironment and the immune system for novel treatments of cancer, autoimmune, metabolic and other diseases

We are addressing immunotherapy and gene therapy of complex diseases through the important role of lipid assembly structures

Human cells are composed of lipid bilayers as their primary structure. HighField takes advantage of this role of lipids in the body to treat a broad range of diseases.

Lipids self-assemble into fascinating structures, and we design these structures to target different cells in complex disease biology.

Our cancer therapies attack cancer cells directly or modulate immune cells in the tumor microenvironment. Our lipid nanoparticles for gene therapy are nontoxic and provide for long-term therapeutic effect.

Lipid-based Antibody Drug Complex Platform

Our lead oncology program, designated K1, is a Lipid-based Antibody Drug Complex (ADCplex™) targeting cancer cells directly

Kl is a lipid bilayer system with targeting antibodies directed to tumor-associated antigens. Kl also carries a drug payload of doxorubicin which is a known anticancer agent.

By optimizing the antibody, lipid and drug components in the system, our series of ADCplex products were shown to effectively bind and deliver various chemotherapy drugs in relevant animal models.

Given the animal model experience, K1 has been approved for human trials for a broad range of cancers including breast, bladder, pancreatic, ovarian, stomach, colon, prostate, lung, uterine and cervix cancers.

The ADCplex system can be compared to current antibody-drug conjugate products. However, Kl offers efficacy with less toxic drug payloads but higher drug to antibody ratios (DAR).

Lipid Nanoparticles for Gene Therapy of Chronic Diseases

Our lead gene therapy candidate is HFG1, an mRNA-based GLP-1R agonist

HFG1 was shown in animal models to be able to produce GLP-1RA that persists longer for a lasting therapeutic effect. It requires less frequent and fewer injections than existing GLP-1 products for diabetes and obesity.

We developed LNPs with membrane stabilized structures (mLNP). Unlike LNPs for mRNA vaccination, mLNPs are stable both under storage stress conditions and in physiological medium. We can manipulate the LNP surface property in order to target to different cell surface ligands, or accumulate in certain tissues for more localized effects.

By applying our LNP technology we enable the use of gene therapy for diabetes and obesity

The Highfield Advantage

Our products are built upon our unique capability to optimize components of lipids for specific targets and mechanisms for treating diseases. Combined with our proprietary system that consistently produces high-quality lipid structures, HighField can produce therapeutics with maximum efficacy and safety.

HighField News

Press Releases

HighField Biopharmaceuticals Dosed First Patient in Phase 1 Trial of Liposomal T Cell Engager HF50 (TCEplex)

•

July 16, 2025

HighField in the News

BioSpace: Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

Recent Publications

ASCO 2025 Abstract: First in human PK analysis of antibody conjugated liposome encapsulating doxorubicin (HF-K1) in advanced cancer patients: Comparison with ADCs.